{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Sweden Drug Manufacturers - Specialty & Generic news", "home_page_url": "https://sharemaestro.com/newsreel/se/healthcare/drug-manufacturers-specialty-generic/", "feed_url": "https://sharemaestro.com/newsreel/se/healthcare/drug-manufacturers-specialty-generic/feed.json", "description": "Latest Drug Manufacturers - Specialty & Generic company headlines from Sweden, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:1ccb6d99c5cf0b92518425bf43eb9ae2dd5e9d8799ba160e8c558c14d02bf601", "url": "https://finance.yahoo.com/healthcare/articles/sobi-enters-strategic-partnership-innate-063600544.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sobi-enters-strategic-partnership-innate-063600544.html", "title": "Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma", "content_text": "STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi\u00ae) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) (\"Innate\" or the \"Company\") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing ", "date_published": "2026-08-10T06:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "SOBI"], "_sharemaestro": {"country": "Sweden", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SOBI", "name": "Swedish Orphan Biovitrum AB (publ)", "sentiment_url": "https://sharemaestro.com/sentiment/24740157-b105-49f6-b0a8-742fd62565fa/"}]}}]}